HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial–mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/β-catenin signaling activation

Wei Tian,Jiatong Li,Zhuo Wang,Tong Zhang,Ying Han,Yanyan Liu,Wenfeng Chu,Yu Liu,Baofeng Yang
DOI: https://doi.org/10.1016/j.apsb.2021.03.040
IF: 14.903
2021-06-01
Acta Pharmaceutica Sinica B
Abstract:<p>HYD-PEP06, an endostatin-modified polypeptide, has been shown to produce effective anti-colorectal carcinoma effects through inhibiting epithelial–mesenchymal transition (EMT). However, whether HYD-PEP06 has similar suppressive effect on hepatocellular carcinoma (HCC) remained unknown. In this study, HYD-PEP06 inhibited metastasis and EMT but not proliferation <em>in vitro</em>. Cignal finder pathway reporter array and Western blot analysis revealed that HYD-PEP06 suppressed HCCLM3 cell metastasis and EMT by inhibiting the PI3K/AKT pathway. Moreover, HYD-PEP06 exerted anti-metastasis effects in HepG2 cancer stem-like cells (CSCs) <em>via</em> suppressing the WNT/<em>β</em>-catenin signaling pathway. Finally, in HepG2 tumor-bearing BALB/c <em>nu</em>/<em>nu</em> nude mice, HYD-PEP06 substantially suppressed tumor growth, lung metastasis and HCC progress. Our results suggest that HYD-PEP06 inhibits the metastasis and EMT of HCC and CSCs as well, and thus has the potential as an agent for HCC treatment.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?